Omas see Table 1.Cell-Free DNA Biomarkers in MelanomaAs a control group

Omas see Table 1.Cell-Free DNA Biomarkers in MelanomaAs a control group 63 healthy subjects with less than 50 Autophagy melanocytic nevi (median age 62, range 25?9 years) were enrolled in the study upon a dermatological examination to exclude the presence of melanoma and to provide the number of nevi. Blood samples (5 ml) were collected in EDTA tubes during the dermatologic examination and before surgery. The research protocol was approved by the review board of the University of Florence and all the patients signed an informed consent. Plasma was separated from blood in EDTA tubes, within three hours from blood draw by two centrifugation steps at 4uC for 10 min: at 1600 rcf and 14000 rcf, respectively. Plasma aliquots (505 ml) were stored at 280uC. DNA was extracted from 500 ml of plasma within 3 months from collection, by the QIAamp DSP Virus Kit (Qiagen, Italy) according to the manufacturer’sinstructions. RNAse digestion was included in the procedure to prevent RNA interference during the subsequent qPCR reactions.Molecular biomarkers in cfDNAAll the cfDNA samples from melanoma patients and healthy controls were submitted in duplicate to the four qPCR assays targeting the chosen biomarkers, for a total of about 1000 determinations. All the qPCR reactions were performed using the 7900HT Fast Real-Time PCR instrument (Applied Biosystems). All the methods described in the following section have been previously developed or optimized for cfDNA by our laboratory using plasma samples from different case studies. The total amount of cfDNA as well as the DNA integrity index were determined by two qPCR assays targeting respectively a 67 bp and a 180 bp sequence on the single copy gene APP (Amyloid Precursor protein, chr. 21q21.2, accession NM_000484),Figure 1. Biomarkers distribution in cases and controls. Box plots reflecting the distribution in cases and controls of total cfDNA (Panel A), integrity index 180/67 (Panel B), methylated RASSF1A (Panel C), and BRAFV600E (Panel D). Each box indicates the 25th and 75th Epigenetic Reader Domain percentiles. The horizontal line inside the box indicates the median, and the whiskers indicate the extreme measured values. doi:10.1371/journal.pone.0049843.gCell-Free DNA Biomarkers in MelanomaTable 2. Descriptive Statistics.25th centile 11.098 2.530 0.560 0.290 0.000 0.000 0.006 0.010 75th centile 30.785 8.740 0.950 0.670 11.040 0.000 0.610 0.biomarker total cfDNA (ng/ml plasma) cases controls integrity index 180/ cases 67 controls methylated RASSF1A cases (GE/ml plasma) controls BRAFV600E (ng/ml plasma) cases controlsmin 0.894 0.990 0.070 0.090 0.000 0.000 0.000 0.median 15.641 5.260 0.750 0.460 0.000 0.000 0.200 0.max 208.560 47.490 2.568 1.810 208.680 4.010 37.338 5.IQR 19.687 6.210 0.390 0.380 11.040 0.000 0.603 0.p-value{ ,0.,0.0.0.Abbreviations: IQR, Interquartile range (75th centile ?25th centile). { p-value of the Kolmogorov-Smirnov test by comparing the distribution of cases and controls. doi:10.1371/journal.pone.0049843.tas already reported [26]. The primers and the hydrolysis probe for the 67 bp amplicon were previously reported [27], while for the 180 bp amplicon a different reverse primer was designed on the same target sequence [26]. The shorter amplicon (67 bp) was used to quantify total cfDNA, while the ratio between the absolute concentration of the longer amplicon (180 bp) and the shorter one (67 bp) defined the integrity 23115181 index 180/67, which was used to assess the fragmentation of cfDNA. An integrity index close to 1 indi.Omas see Table 1.Cell-Free DNA Biomarkers in MelanomaAs a control group 63 healthy subjects with less than 50 melanocytic nevi (median age 62, range 25?9 years) were enrolled in the study upon a dermatological examination to exclude the presence of melanoma and to provide the number of nevi. Blood samples (5 ml) were collected in EDTA tubes during the dermatologic examination and before surgery. The research protocol was approved by the review board of the University of Florence and all the patients signed an informed consent. Plasma was separated from blood in EDTA tubes, within three hours from blood draw by two centrifugation steps at 4uC for 10 min: at 1600 rcf and 14000 rcf, respectively. Plasma aliquots (505 ml) were stored at 280uC. DNA was extracted from 500 ml of plasma within 3 months from collection, by the QIAamp DSP Virus Kit (Qiagen, Italy) according to the manufacturer’sinstructions. RNAse digestion was included in the procedure to prevent RNA interference during the subsequent qPCR reactions.Molecular biomarkers in cfDNAAll the cfDNA samples from melanoma patients and healthy controls were submitted in duplicate to the four qPCR assays targeting the chosen biomarkers, for a total of about 1000 determinations. All the qPCR reactions were performed using the 7900HT Fast Real-Time PCR instrument (Applied Biosystems). All the methods described in the following section have been previously developed or optimized for cfDNA by our laboratory using plasma samples from different case studies. The total amount of cfDNA as well as the DNA integrity index were determined by two qPCR assays targeting respectively a 67 bp and a 180 bp sequence on the single copy gene APP (Amyloid Precursor protein, chr. 21q21.2, accession NM_000484),Figure 1. Biomarkers distribution in cases and controls. Box plots reflecting the distribution in cases and controls of total cfDNA (Panel A), integrity index 180/67 (Panel B), methylated RASSF1A (Panel C), and BRAFV600E (Panel D). Each box indicates the 25th and 75th percentiles. The horizontal line inside the box indicates the median, and the whiskers indicate the extreme measured values. doi:10.1371/journal.pone.0049843.gCell-Free DNA Biomarkers in MelanomaTable 2. Descriptive Statistics.25th centile 11.098 2.530 0.560 0.290 0.000 0.000 0.006 0.010 75th centile 30.785 8.740 0.950 0.670 11.040 0.000 0.610 0.biomarker total cfDNA (ng/ml plasma) cases controls integrity index 180/ cases 67 controls methylated RASSF1A cases (GE/ml plasma) controls BRAFV600E (ng/ml plasma) cases controlsmin 0.894 0.990 0.070 0.090 0.000 0.000 0.000 0.median 15.641 5.260 0.750 0.460 0.000 0.000 0.200 0.max 208.560 47.490 2.568 1.810 208.680 4.010 37.338 5.IQR 19.687 6.210 0.390 0.380 11.040 0.000 0.603 0.p-value{ ,0.,0.0.0.Abbreviations: IQR, Interquartile range (75th centile ?25th centile). { p-value of the Kolmogorov-Smirnov test by comparing the distribution of cases and controls. doi:10.1371/journal.pone.0049843.tas already reported [26]. The primers and the hydrolysis probe for the 67 bp amplicon were previously reported [27], while for the 180 bp amplicon a different reverse primer was designed on the same target sequence [26]. The shorter amplicon (67 bp) was used to quantify total cfDNA, while the ratio between the absolute concentration of the longer amplicon (180 bp) and the shorter one (67 bp) defined the integrity 23115181 index 180/67, which was used to assess the fragmentation of cfDNA. An integrity index close to 1 indi.